CB Insights
Technology Market Intelligence
Technology Market Intelligence
Public list: Pharma Startups (6570)
A company that is doing lead inspection and risk assessments in the Tri-State area. The testing is being performed on residential and commercial properties along with all steel structures including, water tanks, towers and bridges. We will test for l...Show all
Company (Acquired)
Phone: 434-975-4300
706 Forest Street
Suite 1
Charlottesville, 22903
Virginia, United States
| Total Funding | Date of Last Funding | |
|---|---|---|
| Upstate Group | $17.1M | Oct 5, 2004 |
| See all 15 competitors | ||
| Per Week | Per Month | Per 6 Months | Per Year | |
|---|---|---|---|---|
| Rank | Login to see details | |||
| Page Views Per Million | Login to see details | |||
| Page Views Per User | Login to see details | |||
| Reach Per Million | Login to see details | |||
| Investor | Investor Type | Location | Participating Rounds |
|---|
| Company | Status | Description | Investors |
|---|---|---|---|
| Mountain View, California, United States | Acquired | MAP Pharmaceuticals is a drug company focused on providing better treatments for patients with neurological diseases. Taking an integrated scientific approach, MAP Pharmaceuticals seeks to place better care into patients' hands by enhancing how proven drugs perform, through targeted dosing regimens and novel delivery systems. MAP Pharmaceuticals' goal is to develop treatments that provide patients with greater control, improved efficacy and fewer side effects. Development programs in neurolog...Show all | Login to see details |
| Salt Lake City, Utah, United States | Alive / Active | Inflabloc Pharmaceuticals, Inc. is engaged in the research and development of pharmaceutical treatments for inflammatory disorders. Inflabloc's current product development is based on its discoveries of strong anti-inflammatory properties of dehydroepiandrosterone (DHEA), a steroid that is produced in the adrenal gland. The company's lead product line is a DHEA combination treatment. The company has 4 products in development. IP-1001 is slated to enter Phase 2 clinical trials in Crohn's disease ...Show all | Login to see details |
| Title | Application Date | Patent Date | Status (Patent / Application) |
|---|
